In the News
The Burrill Report interviews Greg Scott on WuXi/CRL breakup and China's hot IPOs
 
Greg Scott joined Foley's Eye on China webinar on life science innovation
>>Foley webinar...
Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

>> Preview...

AlphaRx to Seek China Approval of Arthritis Drug Indaflex™

publication date: Feb 1, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

AlphaRx (OTCBB: ALRX) has begun applying for approval of Indaflex™ in China as a treatment for osteoarthritis, with hopes that the application will be complete by April 2008. If the request is accepted, AlphaRx will conduct a clinical trial of Indaflex™ in China, enrolling 240 patients in a two-arm trial that will treat patients for four weeks. AlphaRx anticipates that the trial will be finished by Q4 of 2008. Indaflex™ is a novel formulation of a standard therapy for osteoarthritis, indomethicin. More details...

Stock Symbol: (OTCBB:ALRX)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events
BioBay Investor Forum 2010
Suzhou, China
November 3 - 4, 2010
China Forum 2010
Munich, Germany
November 14, 2010

 
ChinaBio® Investor Forum 2010 - Guangzhou
Guangzhou, China
December 21, 2010
Partner Events
BioPharm America™ 2010
Boston, MA, USA
September 15–17, 2010

CALAsia 2010
San Diego, USA
October 4-5, 2010

CHINA PRETRIALS 2010: Global Preclinical Development Summit
Beijing, China
October 17-19, 2010

CHINA TRIALS 2010
Beijing, China
November 7-9, 2010

12th Shanghai International Forum on Biotechnology & Pharmaceutical Industry (BIO-FORUM)
Beijing, China
November 9-11, 2010
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners